The therapeutic potential of aldose reductase inhibitors for the prevention of the secondary complications of diabetes have been extensively reported.
The therapeutic potential of aldose reductase inhibitors for the prevention of the secondary complications of diabetes have been extensively reported. 1) On the other hand, hyperaggregability of platelets in diabetic patients has also been reported as a cause of chronic diabetic complications. [2] [3] [4] So it seems likely that normalization of aggregability of platelets in diabetic patients may be beneficial for the prevention or the treatment of chronic diabetic complications. Aida et al. reported that isoliquiritigenin (2, 4,2Ј,4Ј-trihydroxychalcone), purified from Glycyrrhizae radix, inhibited RLAR 5) and human platelet aggregation. 6) In a previous paper, we synthesized twenty-four derivatives of 2Ј-hydroxychalcone and their inhibitory effects on RLAR and antioxidant effects have been tested. 7) Some chalcone derivatives synthesized were found to possess AR inhibition and antioxidant activities in vitro as well as inhibition in the accumulation of sorbitol in tissue in vivo, in which 3,4,2Ј,4Ј-tetrahydroxychalcone (18, butein) was the most promising compound for the prevention or treatment of diabetic complications.
This paper describes the inhibitory effects of previously synthesized (A and B series) 7) and newly synthesized chalcones (C series) on RLAR and on rat platelet aggregation. Among these compounds tested only a few were of some importance for further investigations. Table 2 shows the inhibitory activities of 2Ј-hydroxychalcones (A, B and C series) tested on RLAR with DL-glyceraldehyde as a substrate and rat platelet aggregation induced by 2.5 mM ADP and 10.0 mg/ml collagen. Aspirin (As), epalrestat (Ep) and isoliquiritigenin (Iso, 2 in Table 1 ) are also included for comparison.
Results and Discussion
As far as RLAR inhibitory activities are concerned, 11 and 22 of series B exhibited more potent inhibitory effects comparable to Iso, used as positive control. Compound 33 and 36 were most potent in series C, however they were less potent than Iso. The other compounds in series C did not show any significant activity.
The 2Ј,4Ј-dihydroxychalcone derivatives 10-24 (B series), having various functional groups instead of the 4-hydroxy group, showed a potent inhibitory activity on RLAR but possessed a weak anti-platelet activity against ADP and/or collagen except some derivatives. IC 50 values in Table  1 show that the effect of compound tested on collagen-induced platelet aggregation is more sensitive than that on ADP-induced platelet aggregation in rat platelet-rich-plasma (PRP).
As far as inhibition of platelet aggregation is concerned, 5Ј-chloro-4,2Ј-dihydroxychalcone (8) and 5Ј-chloro-3,2Ј-dihydroxychalcone (27) exhibited a strong inhibitory effect comparable with Iso, used as positive control. Figure 1 shows the effects of 27, Iso, Ep and As on the platelet aggregation rate induced by 2.5 mM of ADP (Fig. 1a) and 10.0 mg/ml of collagen (Fig. 1b) . In Fig. 1a , a representative aggregometer tracing representing the effect of compounds on ADP-induced platelet aggregation in rat PRP is shown. Compound 27, Iso and As inhibited the rate of platelet aggregation by 67.3, 41.5 and 30.7% at 75 mg/ml, respectively. Ep, an aldose reductase inhibitor, 8) did not show a significant inhibitory effect at 75 mg/ml. A representative aggregometer tracing representing the effect of compounds on collagen-induced platelet aggregation in rat PRP is shown in Fig. 1b . Compound 27, Iso and As inhibited the rate of platelet aggregation by 52.1, 41.5, and 21.3% at 20 mg/ml, respectively. Ep did not show a significant inhibitory effect at 20 mg/ml.
It has been reported that the inhibitory effect of Iso on platelet aggregation in vitro and in vivo was comparable to that of As and the mechanism by which Iso inhibits platelet aggregation can be explained by its significant effects on the arachidonic acid cascade. 6) These findings may indicate that Iso elicits an anti-platelet action by inhibiting not only cyclooxygenase but also lipoxygenase or peroxidase activity in platelets. Compound 27 was more effective than Iso to inhibit the platelet aggregation induced by ADP and collagen in vitro. Further study of the structure-activity relationships on synthetic compounds is in progress.
Experimental
General Experimental Procedures Melting points (mp) were measured by a Mitamura-Riken melting point apparatus and are uncorrected. Proton ( 1 H-) and carbon ( 13 C-) nuclear magnetic resonance spectra were determined in dimethyl sulfoxide-d 6 and acetone-d 6 on a Varian Gemini 2000 spectrometer at 300 and 75 MHz, respectively. Infrared (IR) spectra were measured by JASCO FT/IR-5000. High resolution mass spectra (HRMS) were taken on a JEOL JMS-AX500WA mass spectrometer. Mass spectra (MS) were taken on a HP 5989B mass spectrometer. Biological activities were measured on a Hitachi U-3210 spectrophotometer and a platelet aggregometer (Chrono-Log, M-500US). Thin-layer chromatographic separations were performed with silica gel 60 F 254 plates (Merck Art. 5715) and silica gel 60 (Merck Art. 7734; 70-230 mesh), respectively.
Chemical 2Ј-Hydroxychalcones (Series A and B) tested were synthesized by the method described in our previous paper. 7) In the case of synthesis of compounds possessing 2Ј,4Ј-or 3,4-dihydroxyl group, the hydroxyl group of the component was protected with methoxymethyl (MOM) using chloro methylmethyl ether.
9) The source of other materials were as follows: 143.6 (C-2), 131.6 (C-3), 145.1 (C-4), 108.9 (C-5), 120. 8 (C-6) shown in Table 2 . Biological Testing. Preparation of RLAR Crude RLAR was prepared as follows: rat lenses were removed from Sprague-Dawley rats weighing 250-280 g and frozen until use. The supernatant fraction of the rat lens homogenate was prepared according to Hayman and Kinoshita 10) and then partially purified according to Inagaki et al.
11) The partially purified material was separated into 1.0 ml aliquots and stored at Ϫ40°C.
Measurements of RLAR Activity RLAR activities were assayed spectrophotometrically by measuring the decrease in absorption of NADPH at 340 nm over a 4 min period with DL-glyceraldehyde as a substrate.
12) Each 1.0 ml cuvette contained equal units of enzyme, 0.10 M sodium phosphate buffer (pH 6.2), 0.3 mM NADPH with or without 10 mM substrate and inhibitor. The concentration of inhibitors giving 50% inhibition of enzyme activity (IC 50 ) was calculated from the least-squares regression line of the logarithmic concentrations plotted against the remaining activity.
Platelet Aggregation Fresh blood, obtained from Sprague-Dawley male rats weighing 250-290 g, containing 0.22% sodium citrate was centrifuged at 1200 rpm for 10 min at room temperature to obtain a supernatant of platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was prepared by re-centrifugation of the remaining blood at 3000 rpm for 15 min. Each compound was dissolved in DMSO and 5 ml of each was added to 485 ml PRP (5ϫ10 5 platelets/ml). Adensosine 5Ј-diphosphate (ADP) and collagen were used as inducers at final concentrations of 2.5 mM and 10.0 mg/ml, respectively. Platelet aggregation was determined by the turbidimetric method using a platelet aggregometer. 13) A water soluble sample was dissolved in saline and 5 ml of this was added to 485 ml PRP, while an insoluble sample in saline was dissolved in DMSO, and 5 ml of this was added to 485 ml PRP. After incubation at 37°C for 1 min with stirring, platelet aggregation was initiated by addition of 10 ml inducer. Saline or DMSO was used as a control. The degree of anti-platelet aggregation (%) was calculated from the following equation; the ratio of anti-platelet aggregation (%)ϭ[1Ϫ(platelet aggregation potency of sample/platelet aggregation potency of the control)]ϫ100. 
